CN105722511B - 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途 - Google Patents

包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途 Download PDF

Info

Publication number
CN105722511B
CN105722511B CN201480062492.5A CN201480062492A CN105722511B CN 105722511 B CN105722511 B CN 105722511B CN 201480062492 A CN201480062492 A CN 201480062492A CN 105722511 B CN105722511 B CN 105722511B
Authority
CN
China
Prior art keywords
eosinophilic
eosinophil
eosinophil driven
compounds
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480062492.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105722511A (zh
Inventor
弗拉迪米尔·叶夫根尼耶维奇·涅博利辛
塔季亚纳·亚历山德罗芙娜·克罗莫瓦
阿纳斯塔西娅·弗拉基米罗夫娜·吕德勒夫斯卡娅
亚历山大·格里戈里耶维奇·舒沙林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemoimmunotherapy LLC
Original Assignee
Chemoimmunotherapy LLC
Pharmenterprises OOO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemoimmunotherapy LLC, Pharmenterprises OOO filed Critical Chemoimmunotherapy LLC
Priority to CN201910373584.XA priority Critical patent/CN110200968A/zh
Publication of CN105722511A publication Critical patent/CN105722511A/zh
Application granted granted Critical
Publication of CN105722511B publication Critical patent/CN105722511B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480062492.5A 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途 Expired - Fee Related CN105722511B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910373584.XA CN110200968A (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2013150861 2013-11-14
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910373584.XA Division CN110200968A (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途

Publications (2)

Publication Number Publication Date
CN105722511A CN105722511A (zh) 2016-06-29
CN105722511B true CN105722511B (zh) 2019-09-17

Family

ID=53057723

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480062492.5A Expired - Fee Related CN105722511B (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途
CN201910373584.XA Pending CN110200968A (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910373584.XA Pending CN110200968A (zh) 2013-11-14 2014-11-12 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途

Country Status (23)

Country Link
US (2) US9949962B2 (enExample)
EP (2) EP3466425B1 (enExample)
JP (4) JP2016540749A (enExample)
KR (2) KR102312294B1 (enExample)
CN (2) CN105722511B (enExample)
AU (2) AU2014349246C1 (enExample)
BR (1) BR112016010515B1 (enExample)
CA (1) CA2930231C (enExample)
CY (1) CY1122500T1 (enExample)
DK (1) DK3069720T3 (enExample)
EA (4) EA032955B3 (enExample)
ES (2) ES2836887T3 (enExample)
HU (1) HUE046671T2 (enExample)
IL (2) IL245429B (enExample)
LT (1) LT3069720T (enExample)
MX (2) MX365781B (enExample)
PL (2) PL3069720T3 (enExample)
PT (1) PT3069720T (enExample)
RU (1) RU2552929C1 (enExample)
SG (1) SG10201900504XA (enExample)
SI (1) SI3069720T1 (enExample)
UA (1) UA118687C2 (enExample)
WO (1) WO2015072893A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
EP2985282A4 (en) * 2013-04-12 2017-02-22 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
MD4788C1 (ro) * 2017-09-07 2022-09-30 Ооо "Валента-Интеллект" Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US20210315941A1 (en) * 2020-04-07 2021-10-14 Hofseth Biocare Asa Respiratory treatments using salmonid oil compositions
WO2021262040A1 (ru) * 2020-06-26 2021-12-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365210A1 (en) * 1988-10-11 1990-04-25 Kyowa Hakko Kogyo Co., Ltd. Hydroxamic acid derivatives
CN106061962A (zh) * 2013-04-12 2016-10-26 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097607A1 (en) 1990-12-24 1992-06-24 Marcel Hibert Use of certain glutarimide derivatives in the treatment of depression and mania
AU6702894A (en) * 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
ES2320638T3 (es) 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365210A1 (en) * 1988-10-11 1990-04-25 Kyowa Hakko Kogyo Co., Ltd. Hydroxamic acid derivatives
CN106061962A (zh) * 2013-04-12 2016-10-26 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法

Also Published As

Publication number Publication date
SG10201900504XA (en) 2019-02-27
DK3069720T3 (da) 2019-11-25
IL271352B (en) 2021-04-29
EP3069720A4 (en) 2017-06-21
JP6758677B2 (ja) 2020-09-23
EA032955B1 (ru) 2019-08-30
EA201891262A1 (ru) 2018-10-31
LT3069720T (lt) 2020-01-10
PL3466425T3 (pl) 2021-04-06
JP2020002152A (ja) 2020-01-09
ES2836887T3 (es) 2021-06-28
PT3069720T (pt) 2019-12-02
EA032955B3 (ru) 2020-02-27
PL3069720T3 (pl) 2020-05-18
JP6589251B2 (ja) 2019-10-16
JP2019055953A (ja) 2019-04-11
SI3069720T1 (sl) 2020-02-28
EP3069720A1 (en) 2016-09-21
AU2014349246B2 (en) 2018-10-18
BR112016010515A2 (enExample) 2017-08-08
EA201990529A1 (ru) 2019-07-31
CA2930231A1 (en) 2015-05-21
RU2552929C1 (ru) 2015-06-10
EP3069720B1 (en) 2019-10-30
CN105722511A (zh) 2016-06-29
IL245429B (en) 2020-02-27
EP3466425B1 (en) 2020-10-07
EA201690798A1 (ru) 2016-08-31
EA037447B1 (ru) 2021-03-30
BR112016010515B1 (pt) 2022-09-27
MX2019006881A (es) 2019-08-01
CN110200968A (zh) 2019-09-06
IL245429A0 (en) 2016-06-30
MX2016006330A (es) 2016-09-06
US20160279114A1 (en) 2016-09-29
KR20200053639A (ko) 2020-05-18
UA118687C2 (uk) 2019-02-25
CA2930231C (en) 2022-06-14
AU2014349246A1 (en) 2016-05-19
MX386887B (es) 2025-03-19
JP2016540749A (ja) 2016-12-28
EA030961B1 (ru) 2018-10-31
KR102312013B1 (ko) 2021-10-15
US10220029B2 (en) 2019-03-05
JP2019214606A (ja) 2019-12-19
US9949962B2 (en) 2018-04-24
EA032940B1 (ru) 2019-08-30
HUE046671T2 (hu) 2020-03-30
KR102312294B1 (ko) 2021-10-15
AU2014349246A9 (en) 2018-09-20
IL271352A (en) 2020-01-30
RU2013150861A (ru) 2015-05-20
CY1122500T1 (el) 2021-01-27
KR20160078400A (ko) 2016-07-04
ES2759530T3 (es) 2020-05-11
AU2014349246C1 (en) 2019-02-21
EA201891261A1 (ru) 2018-10-31
EP3069720A8 (en) 2017-10-04
WO2015072893A1 (ru) 2015-05-21
AU2018264084C1 (en) 2020-08-27
AU2018264084B2 (en) 2020-05-14
AU2018264084A1 (en) 2018-12-06
MX365781B (es) 2019-06-13
EP3466425A1 (en) 2019-04-10
US20180104230A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
CN105722511B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途
KR101907712B1 (ko) 무정형 (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산
TWI729059B (zh) 2-羥吲哚化合物
CN115141197B (zh) 一种3-芳杂环取代苯基衍生物及其制备方法与用途
CN118384143A (zh) 用于治疗炎症性病症的化合物和方法
HK1224930B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途
HK40007097B (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK40007097A (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK1224930A1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
CN113637019A (zh) 一种选择性jak1抑制剂化合物及其制备方法和用途
CN118515598A (zh) 甲异靛的多晶型和甲异靛的改进制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224930

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20190822

Address after: Moscow

Applicant after: Chemoimmunotherapy LLC

Address before: Moscow

Applicant before: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190917

CF01 Termination of patent right due to non-payment of annual fee